-
2 weeks ago | 
nature.com | Andreas Hochhaus |Dong-Wook Kim |Jorge Cortés |Koji Sasaki |Michael J. Mauro |Timothy Hughes | +7 more
AbstractAsciminib is the first approved BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP). The present final analysis of the phase 1, open-label, nonrandomized trial (NCT02081378) assessed the long-term safety, tolerability, and antileukemic activity of asciminib in 115 patients with chronic myeloid leukemia in chronic phase without the BCR::ABL1T315I mutation who received asciminib 10–200 mg twice daily (BID) or 80–200 mg once daily (cutoff: March 14, 2023).
-
1 month ago | 
dialnet.unirioja.es | Jorge Cortés |Martha Carolina Valderrama-Rios |Ángela María Tobón |Beatriz Gomez
Ayuda Buscar en la ayuda Buscar en la ayuda Guía de práctica clínica para el diagnóstico y tratamiento de la histoplasmosis en personas adultas que viven con el VIH - versión corta Autores: Jorge Alberto Cortés, Martha Carolina Valderrama-Ríos, Ángela María Tobón, Beatriz L.
-
Jan 10, 2025 | 
onclive.com | Jorge Cortés |Stephen A. Strickland
OpinionVideoJanuary 10, 2025Author(s):,Panelists discuss how it is an exciting time for chronic myeloid leukemia (CML) treatment, with many options including 6 different drugs that have been very successful for patients, which give clinicians multiple options to tailor the therapy to their patients and consider whether CML could be curable. Video content above is prompted by the following:What are closing thoughts from you on what we’ve discussed today?
-
Jan 10, 2025 | 
onclive.com | Jorge Cortés |Stephen A. Strickland
OpinionVideoJanuary 10, 2025Author(s):,Panelists discuss how a clinician seeks guidance on implementing asciminib in first-line chronic myeloid leukemia treatment following its FDA approval, including understanding its trial data and determining appropriate patient selection compared with existing tyrosine kinase inhibitor options. Video content above is prompted by the following:Can you tell us about the trial design, key end points, and your impressions of the data?
-
Nov 22, 2024 | 
dialnet.unirioja.es | Alexis Rodriguez |Alexis Rodríguez |Jorge Cortés |Sandoval Gutiérrez |Guaria Cárdenas Sandí
Ayuda Buscar en la ayuda Buscar en la ayuda Radiolarians (Class Polycystina) indeep-sea sediments from the Pacific Ocean off Costa Rica Rodríguez–Jiménez, Alexis [1] ; Sandoval Gutiérrez, María Isabel [1] ; Cárdenes Sandí, Guaria [1] ; Cortés, Jorge [2] [1] Escuela Centroamericana de Geología, Facultad de Ciencias, Universidad de Costa Rica, San José, Costa Rica. [2] 1.
-
Nov 7, 2024 | 
energias-renovables.com | Jorge Cortés
Me gusta el concepto de inteligencia artificial. Algunos lo ven como una amenaza al empleo, a la humanización de nuestras relaciones o, incluso, a la propia existencia y sometimiento del hombre por parte de las máquinas. Yo en cambio lo percibo como una oportunidad para que desempeñe tareas que no aporten valor, por repetitivas o sencillas, o todo lo contrario, pues la IA bien entrenada puede ofrecernos ventajas en el día a día.
-
Oct 21, 2024 | 
onclive.com | Jorge Cortés
Jorge E. Cortes, MD, director, Georgia Cancer Center, Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer, Augusta University, discusses efficacy and safety findings from the phase 4 BYOND study (NCT02228382) investigating bosutinib (Bosulif) in previously treated patients with Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML) and highlights the adverse effects (AEs) associated with the treatment.
-
Sep 3, 2024 | 
soziable.es | Jorge Cortés
A continuación se muestra la política de privacidad (en adelante, “política de privacidad web” o “política”) que rige la Plataforma Web https://www.soziable.es/ (en adelante, “la Plataforma”), bajo la titularidad de la ILUNION RETAIL Y COMERCIALIZACIÓN, S.A.U. (en lo sucesivo, “ILUNION RETAIL Y COMERCIALIZACIÓN” o “nosotros”). POR FAVOR, DEDICA UNOS MINUTOS A LEER NUESTRA POLÍTICA DE PRIVACIDAD, NO TE LLEVARÁ MUCHO TIEMPO.
-
Sep 2, 2024 | 
nature.com | Elias Jabbour |Jane F. Apperley |Jorge Cortés |Michael Deininger |Elisabetta Abruzzese |Daniel DeAngelo | +2 more
Correction to: Leukemia https://doi.org/10.1038/s41375-024-02159-0, published online 29 January 2024Following publication of the article, the authors realized that several data points in Figure S3B and the accompanying manuscript text were incorrect. This oversight has been addressed and the corrected figure has been added. 1.
-
Aug 29, 2024 | 
cancernetwork.com | Rohit Gosain |Rahul Gosain |Jorge Cortés
Adverse Events and Clinical Pearls on TKI Utilization in CMLJorge Cortes, MD, provides clinical insights on the utilization of TKIs in CML and outlines associated adverse events.
